Tam-Peli improves survival in relapsed small-cell lung cancer

The International Association for the Study of Lung Cancer (IASLC) presented data from the phase 3 TAISHAN‑302 trial at its 2026 World Conference on Lung Cancer, reporting that tambotatug pelitecan (Tam‑Peli, YL201), a novel anti‑B7‑H3 antibody‑drug conjugate, significantly extended overall survival, progression‑free survival and objective response rate in patients with relapsed small‑cell lung cancer (SCLC) when compared with the standard chemotherapy agent topotecan. The multicenter, randomized study enrolled adults whose disease had progressed after first‑line therapy and assigned them to receive either Tam‑Peli or topotecan, with the antibody‑drug conjugate demonstrating a statistically meaningful advantage across all primary efficacy endpoints.

The trial’s results suggest that targeting the B7‑H3 antigen may offer a new therapeutic avenue for a disease that historically has limited treatment options after relapse. Researchers noted that the safety profile of Tam‑Peli was comparable to that of topotecan, with no new safety signals identified. The findings are expected to inform upcoming regulatory discussions and could potentially reshape the standard of care for relapsed SCLC pending further review.